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background: Recent advancement of minimum volume vitriﬁcation methods has resulted in a dramatic increase in the efﬁciency of the
process. The aim of this study was to estimate the cumulative reproductive outcome of a cohort of infertile couples undergoing ICSI and
oocyte vitriﬁcation in restrictive legal conditions, where only a limited number of oocytes could be inseminated per cycle and embryo selec-
tion and cryopreservation were forbidden.
methods: In this prospective longitudinal cohort study, the cumulative ongoing pregnancy rates obtained by the insemination of fresh and
vitriﬁed oocytes from the same cohort were calculated as primary outcome measures. Moreover, the effect of basal and cycle characteristics
on clinical outcomes were assessed.
results: Between September 2008 and May 2009, 182 ICSI cycles were performed where oocyte vitriﬁcation was possible. A total of 104
ﬁrst and 11 second oocyte warming cycles were then performed in non-pregnant patients of the same cohort. The overall ongoing pregnancy
rates obtained in the fresh,and ﬁrstand second warming cycles were37.4, 25.0 and 27.3%, respectively. The overall cumulativeongoing clinical
pregnancyrateobservedperstimulationcyclewas53.3%.Maternalagewastheonlycharacteristicfoundtoinﬂuencethereproductiveoutcome,
with an inverse correlation between the age .40 and the ongoing pregnancy rates (P ¼ 0.04, by Cox regression analysis).
conclusions: High cumulativeongoingpregnancy ratescanbe obtainedwithtransfers ofembryosderivedfromfreshand cryopreserved
oocytes in a typical infertile population. Female age signiﬁcantly affects outcomes in this system.
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Introduction
Cryopreservation of embryos has become an indispensable part of
assisted reproductive techniques. Frozen embryo transfer contributes
25% of all births achieved by assisted reproduction worldwide
(ICMART, 2008), and with systematical application, up to 42% of
implantations can be derived from frozen embryos (Edgar and
Gook, 2007). In many clinics, birth rates after transfer of cryopre-
served embryos are close or identical to those achieved with their
fresh counterparts, increasing considerably the overall success rate
of ART procedures measured by delivery per oocyte aspiration
rates. However, legal issues and moral concerns may restrict the appli-
cation of embryo cryopreservation. Additionally, due to the lack of a
partner it cannot be applied in many cases of fertility preservation with
medical or social indications, and may create controversial issues in
case of divorce or separation of partners.
The most feasible solution for these problems is oocyte cryopreser-
vation. Unfortunately, in spite of the relative early successes (Chen,
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preservation was hampered for a long time by inconsistent efﬁciency
of the available cryopreservation methods (Oktay et al., 2006).
Stepwise adjustments of traditional slow freezing protocols as well
as optimization of minimum volume vitriﬁcation methods
(Arav, 1992; Kuwayama et al., 2005; Kuwayama et al., 2007) have
resulted in breakthroughs in this ﬁeld. Recent prospective randomized
studies in oocyte donation programs (Cobo et al., 2008; Nagy et al.,
2009) have found no signiﬁcant differences between fresh and vitriﬁed
oocytes regarding the in vitro and in vivo developmental potential.
According to a multicenter study, pregnancies and perinatal outcomes
do not appear to be altered by oocyte vitriﬁcation (Chian et al., 2008).
Our recent non-inferiority trial in a standard infertility program indi-
cated that the oocyte vitriﬁcation procedure followed by ICSI is not
inferior to the fresh insemination procedure, with regard to fertiliza-
tion and embryo developmental rates (Rienzi et al., 2010).
This prospective cohort study aimed to evaluate the cumulative
outcome of embryo transfers performed in infertile patients with
the subsequent use of fresh and vitriﬁed human oocytes between Sep-
tember 2008 and May 2009. To meet the Italian law No 40/2004
between March 2004 and May 2009 (Benagiano and Gianaroli,
2004; Rienzi et al., in press), three oocytes were subjected to ICSI
in fresh and warming cycles and all obtained embryos were transferred
without further selection.
Materials and Methods
Study design and outcome measures
The study was design as a prospective longitudinal cohort study. The base-
line characteristics, embryological data, clinical pregnancy rate and ongoing
clinical pregnancy rate were analyzed on a per cycle basis. The cumulative
success rate was analyzed on a per patient basis.
Fertilization and Day 2 embryo development were evaluated under an
inverted microscope at 16–18 and 44–46 h post-insemination, respect-
ively. Fertilized oocytes were considered as morphologically normal
when two equally sized, centrally located pronuclei were visible. Cleavage
stage embryos were evaluated according to a cumulative embryo classiﬁ-
cation scheme (Rienzi et al., 2002). In accordance with this scheme, an
embryo was considered as top quality when it scored 0–1.
Clinical pregnancy was deﬁned as the presence of gestational sac in
Week 7 after transfer. A miscarriage between Week 7 and Week 20
was deﬁned as an abortion. The implantation rate was deﬁned as
number of gestational sacs per transferred embryo.
Ongoing pregnancy was deﬁned when the pregnancy had completed
20 weeks of gestation. The ongoing implantation rate was deﬁned as
number of fetuses with heart activity beyond 20 weeks of gestation per
transferred embryo.
Cumulative ongoing pregnancy rates obtained with fresh and vitriﬁed
oocytes from the same stimulation cycle were determined.
Female age, cause of infertility, basal FSH, stimulation protocol, sperm
quality, number of oocytes retrieved and oocyte incubation time
between retrieval and vitriﬁcation procedure were all assessed for their
effects on clinical outcomes. The study and the informed consent pro-
cedure were approved by the Institutional Review Board of the Clinic.
Target population
All consecutives patients undergoing ICSI treatment in the Centre for
Reproductive Medicine GENERA in Rome between 2 September 2008
and 15 May 2009 were considered for this study. Only patients with super-
numerary oocytes available for cryopreservation were included. A single
fresh attempt was included for each patient.
Ovarian stimulation, oocyte collection,
denudation, evaluation and injection
Two protocols were used for controlled ovarian hyperstimulation:
GnRH-agonist long protocol and GnRH-antagonist protocol as described
previously (Rienzi et al., 2008).
Details of laboratory and embryo transfer procedures were described in
a concomitant study (Rienzi et al., in press). Brieﬂy, oocytes were collected
at 35 h post-hCG administration. After 2–8 h incubation in vitro,
cumulus-oocyte complexes (COCs) were exposed to 40 IU/ml hyaluroni-
dase solution, and the corona radiata was removed mechanically by pipet-
ting. Metaphase II (MII) oocytes were evaluated and selected under a
stereomicroscope. Those with dark cytoplasm, a centrally located granular
area, acuoles or a large polar body were excluded from insemination and
vitriﬁcation.
Selected oocytes were allocated to fresh insemination or vitriﬁcation,
respectively. Both procedures were performed immediately after denuda-
tion. Three oocytes were inseminated by ICSI using previously described
techniques and instrumentations (Rienzi et al., 1998). Each inseminated
oocyte was cultured separately in a 35 ml microdrop up to Day 2 in a
humidiﬁed atmosphere containing 5% O2 and 6% CO2.
As the earlier referred Italian law did not allow any selection between
viable embryos, all obtained viable embryos were transferred back to
the patient 44–48 h after the microinjection procedure to avoid any
potential negative effect of long-term in vitro embryo culture. In warmed
oocyte cycles, embryos were transferred in the course of a natural
cycle. The luteal phase was supported by vaginal micronized progesterone.
Oocyte vitriﬁcation and warming procedures
The vitriﬁcation and warming procedure has been described earlier (Rienzi
et al., 2010). Brieﬂy, oocytes were vitriﬁed by using the Cryotop device
and solutions (Kitazato BioPharma Co., Japan). The ﬁrst equilibration
was performed in 7.5% ethylene glycol (EG) and 7.5% dimethylsulfoxide
(DMSO) at room temperature for 12–15 min. Subsequently, oocytes
were transferred in 15% EG, 15% DMSO and 0.5 M sucrose for 1 min,
then placed on the ﬁlm strip of the Cryotop in a single small drop. The
excess solution was removed to leave just a thin layer around each
oocyte and the Cryotop was submerged into liquid nitrogen, the strip
was covered with the cap and the sample was stored submerged in
liquid nitrogen.
At warming, the cap was removed under liquid nitrogen and the ﬁlm
strip of Cryotop was quickly submerged in 1 ml of 378C warming solution
containing 1.0 M sucrose for 1 min, then oocytes were transferred to a
room temperature solution containing 0.5 M sucrose, and incubated for
3 min. After two subsequent washing procedures in basic medium at
room temperature for 6 min in total, oocytes were transferred into 1ml
culture medium (Cleavage medium, Sage). Degenerated oocytes were
removed from the cohort. Surviving oocytes were cultured at 378C (6%
CO2 and 5% O2) in mini Sanyo incubators (48L, MCO-5M Sanyo,
Japan) for 2 h before ICSI. When possible, oocytes with dark cytoplasm,
vacuoles or signs of degeneration were excluded from insemination.
Sample speciﬁcations and statistical analysis
Baseline characteristics (continuous data: female age, baseline FSH,
number of cumulus corona cell oocyte complexes retrieved, number of
MII obtained, number of oocytes fertilized, number of embryo transferred,
number of oocytes vitriﬁed, number of oocytes warmed) are presented as
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ables are presented as absolute and percentage frequency. Differences
in clinical and ongoing pregnancy and abortion rates between fresh and
vitriﬁed cycles were evaluated with Pearson’s x
2 test with Yates’ continuity
correction and Fisher’s exact test.
The cumulative ongoing pregnancy rates were calculated by life table
analysis and are expressed as percentage probabilities with 95% conﬁ-
dence intervals (CI). Differences between groups were calculated by
Kaplan–Meier procedure.
The effect of covariates (female group of age, infertility factors, basal
FSH, stimulation protocol, number of COCs and MII oocytes retrieved,
sperm quality and oocyte incubation time between retrieval and vitriﬁca-
tion procedure) on clinical outcome were assessed using Cox regression
analysis.
All statistical analyses were performed using R version 2.8.0 (The R
Foundation for Statistical Computing).
Results
There were 408 patients who underwent 456 ICSI cycles with ovarian
stimulation in our centre during the study period. Oocyte vitriﬁcation
was performed for 182 patients in 182 cycles (44.6% of patients,
39.9% of cycles) which represent our patient’s population. Vitriﬁcation
was performed for the following reasons: in 173 cycles supernumerary
oocytes were available; in ﬁve cycles hyperstimulation syndrome
needed to be prevented; in one cycle no sperm was available on
the day of ovum pick-up; and in three cycles for genetic analysis was
performed.
The mean age of the included patients was 35.81+4.19 years
(range 21–43). Infertility factors were endometriosis in 8 cases
(4.4%), male in 76 cases (41.8%), tubal in 39 cases (21.4%), idiopathic
in 43 cases (23.6%), ovulatory in 4 cases (2.2%) and combined in 12
cases (6.6%). Testicular sperm was used in 10 cycles, and in additional
15 cycles less than 500 000 motile spermatozoa were obtained after
preparation. These cycles where grouped as ‘bad sperm quality’ to
analyze the potential negative paternal effect on outcomes.
The mean numbers of recovered COCs and obtained MII oocytes
were 12.8+4.7 (range 6–31) and 10.1+3.50 (range 5–24),
respectively. There were 511 fresh MII oocytes inseminated in 173
cycles (2.95+0.40; range 2–3). The fertilization rate with fresh
oocytes was 87.1% (445/511). All obtained embryos, independent
of their morphological appearance, were transferred. The mean
number of embryos transferred per patient was 2.52+0.59 (range
1–3) in 172 cycles. In nine cycles, fresh ICSI procedure was not per-
formed, for reasons stated above, and all available mature oocytes
were vitriﬁed, and in one cycle no embryo was available for transfer
after fresh ICSI. A total of 1132 oocytes were vitriﬁed (mean
6.22+3.08).
There were 104 ﬁrst and 11 second oocyte warming cycles per-
formed in non-pregnant patients of the same cohort. The mean
numbers of warmed, survived and inseminated MII phase oocytes
were 4.23+1.23; 3.80+0.89 and 2.97+0.16, respectively. The
overall survival rate was 89.7% (437/487). After morphological selec-
tion, 342 oocytes (maximum three per patient) were inseminated.
The fertilization rate with vitriﬁed oocytes was 85.4% (292/342). As
in the fresh cycles, all obtained embryos, independent of their mor-
phological appearance, were transferred. The mean number of
embryos transferred per patient was 2.40+0.80 (range 1–3). In
four cases, (3.48%) no embryo was available for transfer.
Baseline patient’s characteristics, as well as laboratory outcomes of
fresh and warmed cycles, are shown in Table I. No differences in fer-
tilization rates (87.1 and 85.4%, respectively) and top quality Day 2
embryo rates (58.7 and 57.9%, respectively) were observed
between fresh and vitriﬁed cycles.
Clinical outcomes according to the female’s age are shown in
Table II. The overall ongoing pregnancy rates obtained in the fresh, I
and II warming cycles were 37.4% (68/182), 25.0% (26/104) and
27.3% (3/11), respectively (P ¼ 0.05). Regarding the different age
groups, ongoing pregnancy rates of: 40.3% (29/72), 45.7% (16/35)
and 0% (0/2) were observed in women aged ,34 years (NS);
41.7% (20/48), 11.1% (3/27) and 33.3% (1/3) in women aged 35–
37 years (P ¼ 0.02); 36.6% (15/41), 20.0% (5/25) and 20.0% (1/5)
in women aged 38–40 years (NS); and 19.0% (4/21), 11.8% (2/17)
and 1/1 (100%) in women aged 41–43 years (NS).
The highest achieved cumulative ongoing pregnancy rate (62.5%)
was obtained in the 34 years group. The ongoing clinical pregnancy
rate showed a declining tendency with the increasing maternal age
(Table III). A signiﬁcant difference was found between age group
,34 years and age group 41–43 years (P ¼ 0.006).
According to the Cox regression analysis, infertility factors, basal
FSH levels, stimulation protocols, number of retrieved COCs and
MII, sperm quality and oocyte incubation time between retrieval and
vitriﬁcation all did not inﬂuence the ongoing pregnancy rates. An
inverse correlation was found between the maternal age .40 and
the ongoing pregnancy rates (Table IV).
Table I Baseline patient’s characteristics, fresh and
warming cycles laboratory outcomes.
Baseline patient’s characteristics
No. patients 182
Mean age (mean+SD) 35.81+4.19
Mean basal FSH (mean+SD) 6.5+2.23
Agonist protocol (%) 143/182 (78.6%)
Antagonist protocol (%) 39/182 (21.4%)
Fresh cycle: laboratory outcomes
COC (mean+SD) 12.8+4.7
MII (mean+SD) 10.1+3.5
Inseminated MII (mean+SD) 2.95+0.40
2 PN (mean+SD) 2.57+0.61
Top quality embryos (mean+SD) 1.51+0.96
Embryo transferred (mean+SD) 2.52+0.59
Oocyte vitriﬁed (mean+SD) 6.22+3.08
Warmed cycles: laboratory outcomes
Warmed MII (mean+SD) 4.23+1.23
Survived MII (mean+SD) 3.80+0.89
Inseminated MII (mean+SD) 2.97+0.16
2 PN (mean+SD) 2.54+0.65
Top quality embryos (mean+SD) 1.47+0.91
Embryo transfer (mean+SD) 2.40+0.80
COC, cumulus-oocyte complex; MII, metaphase II; PN, pronucleus.
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failed to complete the ﬁrst and second warming cycle, respectively.
The average numbers of available oocytes per patients are 5.22+
2.41 (n ¼ 47) and 4.94+2.26 (n ¼ 89) for the ﬁrst and second
warming cycle, respectively. Moreover, 509 vitriﬁed oocytes are still
available in the pregnant patient group.
Discussion
Until recently, cryopreservation of human oocytes was regarded as an
inconsistent and generally inefﬁcient procedure; accordingly its appli-
cation was restricted to very special situations where alternative sol-
utions were not available (Porcu et al., 2000; Borini et al., 2004, 2008).
In spite of the difﬁculties related to the oocyte structure and its
cryosensitivity, considerable advancement has been achieved in tra-
ditional slow freezing during the past decade (Boldt et al., 2006;
Borini et al.,2006a, b, 2008), however, results achieved with frozen
occytes compared with sibling fresh oocytes are still different (Magli
et al., 2009). In parallel, and in spite of concerns and aversions,
certain techniques based on the vitriﬁcation (i.e. ice-free cryopreserva-
tion) approach have gained an increasing acceptance (Kuwayama et al.,
2005, 2007; Selman et al., 2006; Lucena et al., 2006; Antinori et al.,
2007; Yoon et al., 2007; Cobo et al., 2008; Chian et al., 2008; Sher
et al., 2008; Nagy et al., 2009; Kim et al., 2009; Rienzi et al., in
press). The minimum volume vitriﬁcation methods including the
Cryotop technique (Kuwayama et al., 2005) used in our study to
.............................................................................................................................................................................................
Table II Clinical outcomes of fresh, and warming cycles according to female age.
Overall 34 years 35–37 years 38–40 years 41–43 years
Fresh cycles: clinical outcomes
No. of cycles 182 72 48 41 21
No. of ET 172/182 (94.5) 66/72 (91.6) 46/48 (95.8) 40/41 (97.6) 20/21 (95.2)
Clinical pregnancy rate per cycle 77/182 (42.3)
a 32/72 (44.4) 22/48 (45.8) 18/41 (43.9) 5/21 (23.8)
Clinical pregnancy rate per ET 77/172 (44.8)
b 32/66 (48.5) 22/46 (47.8) 18/40 (45.0) 5/20 (25.0)
Implantation rate 101/435 (23.2)
c 46/153 (30.0) 29/116 (25.0)
f 21/112 (18.7) 5/54 (9.2)
Abortion rate 9/77 (11.7) 3/32 (9.4) 2/22 (9.0) 3/18 (16.7) 1/5 (20.0)
Ongoing pregnancy rate per fresh cycle 68/182 (37.4)
d 29/72 (40.3) 20/48 (41.7)
g 15/41 (36.6) 4/21 (19.0)
Ongoing implantation rate 90/435 (20.7)
e 42/153 (27.4) 26/116 (22.4)
h 18/112 (16.1) 4/54 (7.4)
Warmed cycles: clinical outcomes
No. of cycles 115 37 30 30 18
No. of ET 111 (96.5) 35/37 (94.6) 29/30 (96.7) 30/30 (100) 17/18 (94.4)
Clinical pregnancy rate per cycle 35/115 (30.4)
a 17/37 (45.9) 7/30 (23.3) 7/30 (23.3) 4/18 (22.2)
Clinical pregnancy rate per ET 35/111 (31.5)
b 17/35 (48.6) 7/29 (24.1) 7/30 (23.3) 4/18 (22.2)
Implantation rate 43/266 (16.1)
c 21/77 (27.3) 8/73 (10.9)
f 9/75 (12.0) 5/41 (12.2)
Abortion rate 6/35 (17.1) 1/17 (5.9) 3/7 (42.8) 1/7 (14.3) 1/4 (25.0)
Ongoing pregnancy rate per warmed cycle 29/115 (25.2)
d 16/37 (43.2) 4/30 (13.3)
g 6/30 (20.0) 3/18 (16.6)
Ongoing implantation rate 35/266 (13.2)
e 19/77 (24.7) 5/73 (6.8)
h 8/75 (10.7) 3/41 (7.3)
Data are expressed as absolute and percentage frequency. ET, embryo transfer.
a,b,c,d,e,f,g,hP , 0.05.
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Table III Cumulative ongoing pregnancy rate after the fresh cycle, ﬁrst warming cycle and second warming cycle
according to female age.
Overall 34 years 35–37 years 38–40 years 41–43 years
Fresh cycle 68/182 (37.4%) 29/72 (40.3%) 20/48 (41.7%) 15/41 (36.6%) 4/21 (19.0%)
(95% CI) (31.2–45.1) (29.7–51.9) (28.8–55.8) (23.6–52.0) (7.8–40.3)
I warming cycle 94/182 (51.6%) 45/72 (62.5%) 23/48 (47.9%) 20/41 (48.8%) 6/21(28.6%)
(95% CI) (44.4–58.8) (50.9–72.8) (34.4–61.7) (34.2–63.6) (13.9–50.2)
II warming cycle 97/182 (53.3%) 45/72 (62.5%)
a 24/48 (50.0%) 21/41 (51.2%) 7/21 (33.3%)
a
(95% CI) (40.0–60.0) (50.9–72.8) (36.3–63.6) (36.4–65.8) (17.2–54.9)
Data are expressed as absolute, percentage frequency and 95% CI.
aP ¼ 0.006.
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chilling injury (Yavin and Arav, 2007), the chance of ice nucleation
(Fuller and Paynter, 2004) and allow the application of a relatively
low cryoprotectant concentration (Vajta and Nagy, 2006; Gardner
et al., 2007).
According to the recent review of Tulandi et al. (2008), pregnancy
rates after oocyte vitriﬁcation are approximately twice as high as after
traditional freezing (10–20 versus 21–45%, respectively). In prospec-
tive randomized studies performed in oocyte donation programs, the
results obtained with vitiﬁed oocytes were similar to those achieved
with fresh counterparts (Cobo et al., 2008; Nagy et al., 2009). The
estimated number of babies born after oocyte cryopreservation is
1000–1200 worldwide (approximate half of them derived from
vitriﬁcation), and the number of reported cases and the contribution
of vitriﬁcation are increasing exponentially.
Unfortunately, even this impressing development seems to be insuf-
ﬁcient. Situations where oocyte cryopreservation offers a realistic sol-
ution also increase exponentially, and the need is at least three orders
of magnitude higher than the actual achievement. Indications of oocyte
vitriﬁcation may be distributed in three distinct groups including (i) fer-
tility preservation for medical or social reasons (Tulandi et al., 2008;
Homburg et al., 2009); (ii) establishment of oocyte banks for donation
programs (Cobo et al., 2008); and (iii) infertility treatment, to replace
embryo cryopreservation.
The latter solution is imperative in countries or situations where
legal or ethical/religious reasons hamper cryopreservation of
embryos but can also be a viable general option to avoid potential
entanglement in case of divorce and separation of couples (Benagiano
and Gianaroli, 2004; Heng, 2007). In a more general sense, cryopre-
servation of supernumerary oocytes instead of embryos may also be
regarded as a step towards decreasing differences between genders
regarding choice in reproduction (Homburg et al., 2009).
The perspective to cryopreserve oocytes instead of embryos in
infertility programs has been outlined earlier (Tucker et al., 2004),
and the recent increase of efﬁciency reported by various groups has
made it a realistic possibility. However, data obtained from a selected
group of young healthy women in oocyte donation programs cannot
be directly applied to patients seeking treatment at an infertility clinic.
In this article, the cumulative ongoing pregnancy rate after transfers
performed with embryos from fresh and vitriﬁed oocytes among
patients in a standard infertility program was analyzed. Principles of
the Cryotop procedure applied for oocyte vitriﬁcation have been
described earlier (Kuwayama et al., 2005; Kuwayama, 2007). Some
technical aspects applied were discussed in detail in our earlier publi-
cation (Rienzi et al., 2010). Efforts were made to minimize oocyte
damage by performing rapid denudation in bicarbonate buffered
media and an appropriate gas atmosphere followed by morphological
selection under a stereomicroscope by using the same media and
environment. The time of in vitro culture of oocytes without the pro-
tection of cumulus-corona radiata cells was decreased to minimal, and
the in vitro culture period after vitriﬁcation was restricted to 2 h.
Our previous work has investigated the in vitro performance of fresh
and vitriﬁed oocytes after insemination with ICSI. The vitriﬁcation pro-
cedure had no detectable effect on the in vitro developmental compe-
tence of oocytes. After ICSI and culture for 2 days, 52% of oocytes
had developed to top quality embryos both from the fresh and vitriﬁed
group. This observation is conﬁrmed by the present study where no
statistical differences were found in the laboratory outcomes
between fresh and vitriﬁed oocytes. Although a negative trend was
observed in the overall clinical outcomes when embryos derived
from vitriﬁed oocytes were transferred, the fresh and vitriﬁed transfer
groups cannot be compared in this study since the former group
included all patients although the latter group included only those
who did not become pregnant after the fresh transfer cycle. Further-
more, the fresh transfer cycle involved ovarian stimulation although
the vitriﬁed transfer was performed in a normal hormonal cycle. Pre-
vious reports (Cobo et al., 2008; Nagy et al., 2009), have found no
difference between pregnancy rates achieved with embryos from
fresh versus vitriﬁed oocytes. These studies were performed in
oocyte donation programs, although our study investigated the appli-
cation of oocyte vitriﬁcation in a standard infertility program. Further
investigations and a different experimental design would be required
to determine whether or not ongoing pregnancy rates after vitriﬁca-
tion are compromised.
Nevertheless, the cumulative ongoing pregnancy rate obtained in
our study was high and comparable with transfer of fresh and cryopre-
served embryos (Ubaldi et al., 2004). With Cox regression analysis,
we did not ﬁnd any association between the etiology of infertility,
stimulation protocol or number of retrieved oocytes and the
ongoing pregnancy rate. The decline of the ongoing pregnancy rate
with augmenting maternal age is a commonly acknowledged phenom-
enon; it has also been conﬁrmed in this study dealing with cumulative
pregnancy rates after oocyte vitriﬁcation in a standard infertility
program. The fact that the patients in general were good responders
........................................................................................
Table IV Effect of patients and cycle characteristics on
cumulative ongoing pregnancy based on Cox regression
analysis (per patient basis).
Covariate P-value OR (95% CI)
Female age groups
 34 years (reference) – – –
35–37 years 0.36 0.78 0.47 to 1.31
38–40 years 0.36 0.77 0.45 to 1.33
41–43 years 0.04 0.44 0.18 to 0.64
Infertility factors
Male (reference) – – –
Idiopathic 0.75 0.90 0.48–1.67
Endometriosis 0.19 0.38 0.09–1.60
Ovulatory 0.54 0.53 0.07–3.91
Tubal 0.81 0.93 0.52–1.65
Combined 0.25 1.56 0.73–3.32
Basal FSH 0.60 0.82 0.82 – 1.23
Number of COC 0.85 1.01 0.92–1.09
Number of MII oocytes 0.57 1.03 0.92–1.14
Incubation time prior to ICSI/
vitriﬁcation
0.77 1.02 0.88–1.17
Stimulation protocol 0.41 0.79 0.45–1.37
Sperm quality 0.84 1.07 0.56–2.03
OR, odds ratio; 95% CI, 95% conﬁdence interval.
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the basal FSH levels, number of oocytes retrieved and ongoing preg-
nancy rates. In contrast to an earlier observation (Parmegiani et al.,
2008), in our study the incubation time between oocyte retrieval
and cryopreservation (up to 8 h) had no inﬂuence on the ongoing
pregnancy rates. These contradicting results may be explained by
the different cryopreservation procedure (slow rate freezing versus
vitriﬁcation). Another possible explanation is that Parmeggiani et al.
had denuded the oocytes up to 1 h before cryopreservation (personal
communication), although in our work the COCs were preserved
during the in vitro incubation until the beginning of the vitriﬁcation pro-
cedure. The lack of relationship with sperm quality may be related to
the exclusive use of ICSI for insemination of both fresh and vitriﬁed
oocytes.
In conclusion, high cumulative ongoing pregnancy rates were
achieved in a standard infertility program with transfers of embryos
derived from fresh and subsequently vitriﬁed oocytes. Among
various infertility factors, only female age inﬂuenced signiﬁcantly the
outcome. The overall efﬁciency justiﬁes the application of this strategy
in routine infertility work.
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